Real world study assessing safety outcomes and infusion chair time savings associated with SC administration in daratumumab naive patients
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab
- Indications Acute myeloid leukaemia; Amyloid light-chain amyloidosis; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Plasmablastic lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 04 Aug 2022 New trial record
- 01 Aug 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia